Astrazeneca PLC’s (AZN) Buy Rating Reiterated at Cantor Fitzgerald
AZN has been the subject of several other reports. Citigroup Inc. reaffirmed a buy rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. set a $41.40 price objective on shares of Astrazeneca PLC and gave the stock a buy rating in a report on Thursday, September 8th. Piper Jaffray Cos. assumed coverage on shares of Astrazeneca PLC in a report on Friday, September 23rd. They set an overweight rating for the company. TheStreet upgraded shares of Astrazeneca PLC from a hold rating to a buy rating in a research note on Friday, July 22nd. Finally, BNP Paribas cut shares of Astrazeneca PLC from an outperform rating to a neutral rating in a research note on Tuesday, September 13th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Astrazeneca PLC presently has an average rating of Buy and a consensus price target of $37.44.
Astrazeneca PLC (NYSE:AZN) opened at 32.26 on Tuesday. The stock has a 50 day moving average of $33.27 and a 200 day moving average of $30.76. The firm has a market capitalization of $81.62 billion, a price-to-earnings ratio of 36.87 and a beta of 0.75. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. Astrazeneca PLC’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 EPS. Equities research analysts anticipate that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were issued a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is currently 78.29%.
Large investors have recently modified their holdings of the company. Forester Capital Management LTD raised its stake in shares of Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. First Interstate Bank raised its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares in the last quarter. Synovus Financial Corp raised its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Finally, Integrated Investment Consultants LLC raised its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. 11.39% of the stock is currently owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.